Clinical Trial Update: BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection [Phase 4]

View source ↗

Summary

Completed Phase 4 trial evaluating Fuzeon (enfuvirtide) delivered via the Needle-Free Biojector 2000 for HIV-1 infection. Sponsor: Hoffmann-La Roche.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Fuzeon (enfuvirtide)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: HIV Infections | Phase 4 | Status: COMPLETED